Clinical Trial

A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a phase III study of SHR-1905 in subjects with severe uncontrolled asthma. The purpose of the study is to evaluate efficacy and safety of SHR-1905 in subjects with severe uncontrolled asthma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-25; most recent amendment 2025-09-08.
Status change: Not Yet Recruiting → Recruiting 2025-08-25
Trial Details
NCT Number NCT07098403
Lead Sponsor Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions Asthma
Enrollment 408 participants
Start Date 2025-09-03
Primary Completion 2028-01 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2025-09-09